QINLOCK® (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) - TC Read more about QINLOCK® (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) - TC
Zai Lab Announces Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in Hong Kong - TC Read more about Zai Lab Announces Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in Hong Kong - TC
Zai Lab Announces Upcoming Presentations in September Investor Conferences - TC Read more about Zai Lab Announces Upcoming Presentations in September Investor Conferences - TC
Zai Lab Announces Second Quarter 2021 Financial Results and Corporate Updates - TC Read more about Zai Lab Announces Second Quarter 2021 Financial Results and Corporate Updates - TC
Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology - TC Read more about Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology - TC
Zai Lab Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Updates - TC Read more about Zai Lab Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Updates - TC
Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer - TC Read more about Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer - TC
Zai Lab to Announce Second Quarter 2021 Financial Results - TC Read more about Zai Lab to Announce Second Quarter 2021 Financial Results - TC
Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology - TC Read more about Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology - TC
Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China - TC Read more about Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China - TC